 
|
| Place of Origin: | China |
| Brand Name: | Top Pharm |
| Certification: | IOS 901 |
| Model Number: | 83150-76-9 |
| Minimum Order Quantity: | 10g |
|---|---|
| Price: | Negotiable |
| Packaging Details: | As your requirments |
| Delivery Time: | 3-6 working days |
| Payment Terms: | T/T, Western Union, MoneyGram,bitcoin |
| Supply Ability: | bulk stock |
| Appearance: | White Loose Lyophilized Powder. | Purity: | 99% |
|---|---|---|---|
| Spec: | 10G | MF: | C19H28O3 |
| MW: | 304.42 | ||
| High Light: | 4 Hydroxy Testosterone,Muscle Gain Formestane Powder,CAS 566-48-3 4 Hydroxytestosterone |
||
4-HYDROXY TESTOSTERONE /Formestane
Product name: 4-Hydroxy Testosterone
Chemical Name: 4-Androsten-4, 17-ol-3-one
CAS: 566-48-3
Molecular Formula: C19H28O3
Molecular weight: 304.42
Standard: Enterprise Standard
4-Hydroxytestosterone is testosterone substituted with a hydroxy group on the fourth carbon atom. It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency.
Formestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one of the many byproducts of formestane metabolism. It is specifically the 17-hydroxylated analog to formestane. 1 Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in 1955 by G.D Searle & Company.
4-Hydroxytestosterone is a DEA Schedule III controlled substance. Substances in the DEA Schedule III have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.
4-Hydroxytestosterone is testosterone substituted with a hydroxy group on the fourth carbon atom. It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency. Formestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one of the many byproducts of formestane metabolism. It is specifically the 17-hydroxylated analog to formestane. Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in 1955 by G.D Searle & Company.
Formestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. Formestane suppresses estrogen production from anabolic steroids or prohormones. Formestane is also a prohormone of 4-hydroxytestosterone, an active steroid with weak androgenic activity and mild aromatase inhibitor activity. It is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes.
Formestane has poor oral bioavailability, and thus must be administered fortnightly (bi-weekly) by intramuscular injection. Some clinical data has suggested that the clinically recommended dose of 250mg was too low. With the discovery of newer, non-steroidal and steroidal, aromatase inhibitors which were orally active and less expensive than formestane, formestane lost popularity.
Currently, formestane (categorized as an anti-estrogenic agent) is prohibited from use in sports in accordance to the regulations of the World Anti-Doping Agency. It is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn.
Formestane is a second generation, irreversible, steroidal aromatase inhibitor. It inhibits the aromatase enzyme responsible for converting androgens to estrogens, thereby preventing estrogen production.
Breast cancer may be estrogen sensitive or insensitive. A majority of breast cancers are estrogen sensitive. Estrogen sensitive breast cancer cells depend on estrogen for viability. Thus removal of estrogen from the body can be an effective treatment for hormone sensitive breast cancers.
Formestane has been targeted specifically for the treatment of postmenopausal women. Unlike premenopausal women who produce most estrogen in the ovaries, postmenopausal women produce most estrogen in peripheral tissues with the help of the aromatase enzyme. Formestane, an aromatase inhibitor, can thus help to decrease the local production of estrogen by blocking the aromatase enzyme in peripheral tissues (ie. adispose tissue of the breast) to treat hormone sensitive breast cancer.
4-hydroxytestosterone is a fat soluble compound which can cross the lipid bilayers of cell membranes to enter the cytoplasm of cells. In the cytoplasm, 4-hydroxytestosterone can bind to an androgen receptor, which then gets transported to the nucleus of the cell to alter protein transcription and translation.
Ananolic steroids are believed to increase muscle mass by increasing the production of proteins, as well as by reducing the effects of the stress hormone cortisol, which is known to promote muscle breakdown. It is postulated that other steroid hormones (glucocorticoids) may also be inhibited by anabolic steroids in order to prevent muscle catabolism.
| Hot Sale | |
| Testosterone enanthate | 315-37-7 |
| Testosterone propionate | 57-85-2 |
| Testosterone cypionate | 58-20-8 |
| Testosterone sustanon | 924-89-0 |
| Nandrolone decanoate(deca) | 360-70-3 |
| Nandrolone phenylpropionate(duabolin) | 62-90-8 |
| Equipoise(boldenone undecylenate) | 13103-34-9 |
| Trenbolone acetate(Finaplix H/Revalor-H) | 10161-34-9 |
| Trenbolone enanthate | 10161-33-8 |
| Drostanolone enanthate(masteron enanthate) | 521-12-0 |
| Methenolone enanthate | 303-42-4 |
| Methenolone acetate | 434-05-9 |
| Dianabol(dbol) | 72-63-9 |
| Anavar | 53-39-4 |
| Anadrol | 434-07-1 |
| Winstrol | 10418-03-8 |
Contact Person: Anne
Tel: +8618702784137
